Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

8.0%

2 terminated/withdrawn out of 25 trials

Success Rate

88.2%

+1.7% vs industry average

Late-Stage Pipeline

24%

6 trials in Phase 3/4

Results Transparency

0%

0 of 15 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 1
13(52.0%)
Phase 2
6(24.0%)
Phase 3
3(12.0%)
Phase 4
3(12.0%)
25Total
Phase 1(13)
Phase 2(6)
Phase 3(3)
Phase 4(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (25)

Showing 20 of 25 trials
NCT06417281Phase 3Completed

Photodynamic Diagnosis for Malignant Brain Glioma With 5-Aminolevulinic Acid(5-ALA)

Role: lead

NCT07455045Phase 1Not Yet Recruiting

A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG)

Role: lead

NCT06424665Phase 1Recruiting

A Study of FZ-AD005 in Patients With Advanced Solid Tumors

Role: lead

NCT05171894Phase 2Recruiting

A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDT

Role: lead

NCT05174637Phase 1Active Not Recruiting

A Study of FDA018-ADC in Patients With Advanced Solid Tumors

Role: lead

NCT06519370Phase 3Active Not Recruiting

FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Role: lead

NCT05914545Phase 1Recruiting

A Study of FZ-AD004 in Patients With Advanced Solid Tumors

Role: lead

NCT04715529Phase 1Completed

Phase 1 Study to Evaluate Safety and Pharmacokinetics of FZJ-003 in Healthy Volunteers

Role: lead

NCT06715319Phase 3Completed

Obeticholic Acid Versus Placebo, in Combination with Ursodeoxycholic Acid in Patients with Primary Biliary Cirrhosis

Role: lead

NCT06413615Phase 2Recruiting

A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors

Role: lead

NCT06439433Phase 2Completed

ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection

Role: lead

NCT05564858Phase 1Recruiting

A Study of FDA022-BB05 in Subjects With Advanced Solid Malignant Tumors

Role: lead

NCT03894150Phase 1Completed

A Study of F0002-ADC in Chinese Patients With Refractory or Recurrent CD30+ Hematologic Malignancies.

Role: lead

NCT03181984Phase 4Completed

Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain

Role: lead

NCT04106258Phase 4Completed

A Pilot Study of Hemoporfin PDT in Children(2-7 Years Old) With Port-wine Stain

Role: lead

NCT04044898Phase 1Completed

Pharmacokinetics and Safety of ALA in Acne Vulgaris

Role: lead

NCT03125057Phase 4Completed

A Pilot Study of Hemoporfin PDT in Children With Port-wine Stain

Role: lead

NCT04018885Phase 1Completed

A Study on Safety and Preliminary Efficacy of ALA in Acne Vulgaris

Role: lead

NCT02955771Phase 2Terminated

Efficacy and Safety Study of PDT Using Deuteporfin for Unresectable Advanced Perihilar Cholangiocarcinoma

Role: lead

NCT02291471Phase 1Completed

Tolerance and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers

Role: lead